Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vigil Neuroscience
Biotech
Vigil's rare brain disease drug flunks phase 2 study
The trial missed its biomarker and efficacy endpoints, prompting the Sanofi-bound biotech to stop a long-term extension trial of the TREM2 agonist.
Nick Paul Taylor
Jun 4, 2025 9:45am
Sanofi inks $470M Vigil buyout to snag Alzheimer's prospect
May 22, 2025 4:49am
Analysts 'highly encouraged' by Vigil's phase 1 Alzheimer's data
Jan 23, 2025 9:51am
FDA greenlights Vigil's Alzheimer's trial—with a partial hold
Sep 11, 2023 12:00pm
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Roche's executive dominoes continue to tip—Chutes & Ladders
Dec 16, 2022 9:30am
